A detailed history of Bellevue Group Ag transactions in Biogen Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 5,902 shares of BIIB stock, worth $1.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,902
Previous 6,008 1.76%
Holding current value
$1.03 Million
Previous $1.3 Million 5.64%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $20,195 - $25,092
-106 Reduced 1.76%
5,902 $1.37 Million
Q1 2024

May 15, 2024

SELL
$212.02 - $267.71 $525,173 - $663,117
-2,477 Reduced 29.19%
6,008 $1.3 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $1.97 Million - $2.37 Million
-8,829 Reduced 50.99%
8,485 $2.2 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $2.1 Million - $2.37 Million
-8,284 Reduced 32.36%
17,314 $4.45 Million
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $246,073 - $284,345
894 Added 3.62%
25,598 $7.29 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $949,272 - $1.08 Million
-3,700 Reduced 13.03%
24,704 $6.87 Million
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $83,557 - $101,524
-331 Reduced 1.15%
28,404 $7.87 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $1.34 Million - $1.85 Million
6,885 Added 31.51%
28,735 $7.67 Million
Q2 2022

Aug 11, 2022

SELL
$187.54 - $223.02 $93,770 - $111,510
-500 Reduced 2.24%
21,850 $4.46 Million
Q1 2022

May 13, 2022

SELL
$193.77 - $244.14 $97.4 Million - $123 Million
-502,650 Reduced 95.74%
22,350 $4.71 Million
Q4 2021

Feb 10, 2022

SELL
$223.92 - $287.77 $447,840 - $575,540
-2,000 Reduced 0.38%
525,000 $126 Million
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $311,289 - $405,955
-1,100 Reduced 0.21%
527,000 $149 Million
Q2 2021

Aug 12, 2021

SELL
$259.0 - $414.71 $7.85 Million - $12.6 Million
-30,300 Reduced 5.43%
528,100 $183 Million
Q1 2021

May 12, 2021

SELL
$242.95 - $284.63 $1.36 Million - $1.59 Million
-5,600 Reduced 0.99%
558,400 $156 Million
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $131 Million - $198 Million
555,400 Added 6458.14%
564,000 $138 Million
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $2.28 Million - $2.63 Million
8,600 New
8,600 $2.44 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $2.2 Million - $2.91 Million
-8,500 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$268.85 - $341.04 $2.15 Million - $2.73 Million
8,000 Added 1600.0%
8,500 $2.69 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $7.01 Million - $9.68 Million
-31,850 Reduced 98.45%
500 $148,000
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $608,832 - $682,864
2,800 Added 9.48%
32,350 $7.53 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $4.63 Million - $5.1 Million
21,100 Added 249.7%
29,550 $6.91 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $3.64 Million - $5.69 Million
-16,800 Reduced 66.53%
8,450 $2 Million
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $3.9 Million - $4.94 Million
-13,995 Reduced 35.66%
25,250 $7.6 Million
Q3 2018

Nov 13, 2018

SELL
$293.51 - $383.83 $29,351 - $38,383
-100 Reduced 0.25%
39,245 $13.9 Million
Q2 2018

Aug 07, 2018

SELL
$257.52 - $306.91 $1.77 Million - $2.1 Million
-6,855 Reduced 14.84%
39,345 $11.4 Million
Q1 2018

May 09, 2018

SELL
$260.13 - $367.91 $1.59 Million - $2.24 Million
-6,100 Reduced 11.66%
46,200 $12.7 Million
Q4 2017

Feb 14, 2018

SELL
$307.64 - $344.58 $2.03 Million - $2.27 Million
-6,600 Reduced 11.21%
52,300 $16.7 Million
Q3 2017

Nov 13, 2017

SELL
$281.15 - $329.69 $730,989 - $857,194
-2,600 Reduced 4.23%
58,900 $18.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
61,500
61,500 $16.7 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.